Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. The most common side effects in people with COVID‑19 is nausea. The expected course of treatment is six vials over five days for a total cost of US$2,340.
About Remdesivir in brief
Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. The most common side effects in people with COVID‑19 is nausea. Side effects may include liver inflammation and an infusion-related reaction with nausea, low blood pressure, and sweating. The expected course of treatment is six vials over five days for a total cost of US$2,340. Being a repurposed drug, the minimum production cost for remdesvir is estimated at US$0. 93 per day of treatment. In the United States, remdesevir is indicated for use in adults and adolescents ) for the treatment of COVID 19 requiring hospitalization. In November 2020, the World Health Organization updated its guideline on therapeutics for COVID-19 to include a conditional recommendation against the use of remdesavir, triggered by results from the WHO Solidarity trial. The European Medicines Agency announced that they will evaluate new data to see if a revision to the authorization of remDesivir is needed. On 27 July 2020, Health Canada approved an application from Gilesad for use for treating COVID19 and severe illness. As of 11 April 2020, access in Canada was only available through clinical trials. On 23 March 2020, Gileads suspended access for compassionate use, for reasons related to supply, citing the need to continue to provide the agent for testing in clinical trials .
On 29 June 2020, Gilead announced that it had set the price of rem Desivir at US$390 per vial for the governments of developed countries, including the U.S., and US$520 for US private health insurance companies. In July 2020,. remdes Vivir was provisionally approved for use. in Australia for use with severe COVID symptoms who have been hospitalized. In Australia, Australia claims to have a sufficient supply of rem DESIVir to use in its national stockpile. On 19 June 2020,. Health Canada received an application for use of remdesivIR for treating COVID 19 and severe illness. On July 27, Canada approved remdesivirs for treating twelve people with CO VID 19 and severely illnesses. In India, India granted emergency marketing approval of generic remdesIVir manufactured by two GileAD licensees, Cipla and Hetero Drugs. In December 2020, the FDA issued an emergency use authorization for the combination of baricitinib with remdesovir, for the treatment of suspected or laboratory confirmed CO VID-19 in hospitalized people two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. In the European Union, rem Desvivir is indicated for thetreatment of coronavirus disease 2019 in adults with pneumonia requiring supplemental oxygen.